United Therapeutics Co. (UTHR) Shares Sold by Texas Permanent School Fund

Share on StockTwits

Texas Permanent School Fund trimmed its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 2.5% in the 3rd quarter, HoldingsChannel reports. The fund owned 27,410 shares of the biotechnology company’s stock after selling 694 shares during the period. Texas Permanent School Fund’s holdings in United Therapeutics were worth $3,505,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of UTHR. Legacy Financial Advisors Inc. purchased a new position in United Therapeutics during the second quarter valued at $107,000. Sun Life Financial INC purchased a new position in United Therapeutics during the second quarter valued at $198,000. Fox Run Management L.L.C. purchased a new position in United Therapeutics during the second quarter valued at $269,000. IFM Investors Pty Ltd purchased a new position in United Therapeutics during the third quarter valued at $301,000. Finally, HL Financial Services LLC grew its stake in United Therapeutics by 32.1% during the second quarter. HL Financial Services LLC now owns 2,711 shares of the biotechnology company’s stock valued at $307,000 after acquiring an additional 658 shares in the last quarter. 94.62% of the stock is owned by institutional investors.

In other United Therapeutics news, Director Christopher Causey sold 810 shares of United Therapeutics stock in a transaction on Thursday, September 6th. The shares were sold at an average price of $118.00, for a total value of $95,580.00. Following the completion of the transaction, the director now directly owns 3,925 shares of the company’s stock, valued at approximately $463,150. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Richard Giltner sold 3,240 shares of United Therapeutics stock in a transaction on Thursday, August 16th. The stock was sold at an average price of $129.38, for a total transaction of $419,191.20. The disclosure for this sale can be found here. Insiders sold a total of 4,860 shares of company stock valued at $611,161 over the last three months. Corporate insiders own 8.20% of the company’s stock.

Several equities analysts recently weighed in on UTHR shares. Zacks Investment Research raised shares of United Therapeutics from a “hold” rating to a “buy” rating and set a $127.00 target price for the company in a research note on Saturday, July 7th. Credit Suisse Group raised their target price on shares of United Therapeutics from $104.00 to $107.00 and gave the company a “neutral” rating in a research note on Tuesday, July 10th. BidaskClub raised shares of United Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, July 11th. Wedbush raised their target price on shares of United Therapeutics from $234.00 to $253.00 and gave the company an “outperform” rating in a research note on Thursday, August 2nd. Finally, HC Wainwright reaffirmed a “hold” rating and set a $95.00 target price on shares of United Therapeutics in a research note on Thursday, August 2nd. Two research analysts have rated the stock with a sell rating, four have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $138.86.

Shares of NASDAQ:UTHR opened at $122.67 on Wednesday. United Therapeutics Co. has a 52 week low of $100.57 and a 52 week high of $152.55. The firm has a market capitalization of $5.16 billion, a price-to-earnings ratio of 11.26, a price-to-earnings-growth ratio of 26.56 and a beta of 1.21. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.64 and a quick ratio of 4.35.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Featured Article: Do Tariffs Work?

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply